Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.92 USD | +0.11% | -4.60% | -36.13% |
05-09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
05-09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.13% | 888M | |
+23.37% | 47.02B | |
+49.56% | 41.86B | |
-0.94% | 41.76B | |
-4.27% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
+30.23% | 12.34B | |
-2.67% | 11.82B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Viridian Therapeutics Starts Underwritten Stock Offering; Shares Fall After Hours